<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771923</url>
  </required_header>
  <id_info>
    <org_study_id>8.1-21/20-2; 02/21AG</org_study_id>
    <nct_id>NCT04771923</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid Versus Adrenaline for Controlling Iatrogenic Endobronchial Bleeding</brief_title>
  <acronym>TAVA</acronym>
  <official_title>Tranexamic Acid Versus Adrenaline for Controlling Iatrogenic Endobronchial Bleeding: a Double Blind, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Hospital Centre Zagreb</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Hospital Centre Zagreb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endobronchial bleeding is a relatively common complication of diagnostic bronchoscopy. Both&#xD;
      tranexamic acid and adrenaline are used topically for the control of endobronchial bleeding.&#xD;
      The aim of this study is to compare the efficacy of tranexamic acid with adrenaline in&#xD;
      controlling iatrogenic endobronchial bleeding after diagnostic bronchoscopy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">February 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage (%) of successfully controlled iatrogenic endobronchial bleeding in each arm</measure>
    <time_frame>Until the end of the individual procedure (bronchoscopy), up to 1 minute after each drug application.</time_frame>
    <description>Bleeding control is assessed by the bronchoscopist by visual confirmation of clot formation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number (N) of tranexamic acid/adrenaline applications necessary to control endobronchial bleeding</measure>
    <time_frame>Until the end of the individual procedure (bronchoscopy), up to 1 minute after each drug application..</time_frame>
    <description>Bleeding control is assessed by the bronchoscopist by visual confirmation of clot formation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (N) of recurrent bleeding episodes after instillation of tranexamic acid/adrenaline</measure>
    <time_frame>During the first 24 hours immediately after the individual procedure (bronchoscopy).</time_frame>
    <description>Recurrent bleeding episodes and hemoptysis requiring medical and/or bronchoscopic intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of successfully controlled iatrogenic endobronchial bleeding in each arm in relation to the severity of bleeding.</measure>
    <time_frame>Until the end of the individual procedure (bronchoscopy), up to 1 minute after each drug application..</time_frame>
    <description>As assessed by the bronchoscopist by visual analogue scale (VAS) 1-10 (1 very mild - 10 very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of successfully controlled iatrogenic endobronchial bleeding in each arm</measure>
    <time_frame>Until the end of the individual procedure (bronchoscopy), up to 1 minute after each drug application.</time_frame>
    <description>In different indications and methods (transbronchial lung biopsy, endobronchial biopsy, transbronchial needle aspiration, bronchial brushing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare number (N) of adverse events in each arm</measure>
    <time_frame>During and up to 1 month after the procedure (bronchoscopy).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bleeding</condition>
  <condition>Hemoptysis</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Adrenaline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>Topical instillation of tranexamic acid up to 3x. If bleeding is not controlled patients crossover to adrenaline.</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adrenaline</intervention_name>
    <description>Topical instillation of adrenaline up to 3x. If bleeding is not controlled patients crossover to tranexamic acid.</description>
    <arm_group_label>Adrenaline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with endobronchial bleeding during diagnostic bronchoscopy that was not&#xD;
             successfully controlled with cold (4°C) normal saline (3 aliquots of 5ml during 60sec)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient with a contraindication for diagnostic flexible bronchoscopy&#xD;
&#xD;
          -  Coagulopathy (PV INR &gt;1.3)&#xD;
&#xD;
          -  Thrombocytopenia (&lt;50x10^9) or anemia (hgb &lt;80 g/L)&#xD;
&#xD;
          -  Direct oral anticoagulant, low molecular weight heparin or antiplatelet drug therapy&#xD;
&#xD;
          -  Thrombophilia, history of pulmonary embolism or deep vein thrombosis&#xD;
&#xD;
          -  Contraindication for endobronchial application of adrenaline&#xD;
&#xD;
          -  Coronary heart disease, cerebrovascular disease, history of tachyarrhythmia&#xD;
&#xD;
          -  Uncontrolled pulmonary hypertension&#xD;
&#xD;
          -  Cardiovascular decompensation&#xD;
&#xD;
          -  Severe hypoxia (PaO2 &lt;60mmHg, SaO2 &lt;90% with an FiO2 &gt;=60%)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sonja Badovinac, MD, PhD</last_name>
    <phone>00385 (1) 2385 129</phone>
    <email>sonjabadovinac1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Goran Glodić, MD</last_name>
    <phone>00385 (1) 2385 129</phone>
    <email>glodic.goran@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonja Badovinac, MD, PhD</last_name>
      <phone>00385 (1) 2385 129</phone>
      <email>sonjabadovinac1@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Goran Glodić, MD</last_name>
      <phone>00385 (1) 2385 129</phone>
      <email>glodic.goran@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Hospital Centre Zagreb</investigator_affiliation>
    <investigator_full_name>Goran Glodić</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Bronchoscopy</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>Adrenaline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoptysis</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

